Over the past five years, it posted a negative one-day return in 55% of cases, with a median drop of 3.0% and a maximum ...

Bristol-Myers Squibb Company's Q1 2025 earnings reveal revenue decline but EPS growth. Click to discover BMY challenges, ...

Despite recent underperformance, Bristol-Myers' strong cash position, robust pipeline, and strategic acquisitions position it for future growth, making it an undervalued opportunity. BMY's growth ...

We recently published a list of 10 Dirt Cheap Stocks To Invest In Now. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other dirt cheap ...

Bristol Myers announced disappointing top-line results from the phase III ARISE study on schizophrenia drug Cobenfy (xanomeline and trospium chloride). The study is evaluating the efficacy and ...

In this article, we are going to take a look at where Bristol-Myers Squibb Co. (NYSE ... and healthcare, can further guide investment choices. Diversification across various sectors reduces ...

Bristol Myers Squibb BMY suffered a setback in the late-stage ODYSSEY-HCM study evaluating cardiovascular drug Camzyos (mavacamten). The phase III study was evaluating Camzyos for the treatment of ...

April 22 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a keenly watched late-stage trial that ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other dirt cheap stocks to invest in now. The stock market has been experiencing ...